businesswire.comOmeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program6 months ago
businesswire.comOmeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program6 months ago
businesswire.comOmeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint7 months ago
businesswire.comOmeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint7 months ago
businesswire.comOmeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting8 months ago
businesswire.comOmeros Corporation Announces Upcoming Presentations at ASH Annual Meeting9 months ago
CashuOmeros Corporation: Key Earnings Report Ahead, Spotlight on Narsoplimab and Innovation3 days ago
CashuOmeros Corporation: Pioneering Biotech Innovations in Neurology and Inflammation Therapy2 months ago